MaxCyte (MXCT) Competitors $2.20 +0.02 (+0.92%) Closing price 04:00 PM EasternExtended Trading$2.20 +0.00 (+0.23%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MXCT vs. ETWO, EEX, UXIN, NRDS, PRSU, IIIV, YEXT, TIXT, RSKD, and TRMRShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include E2open Parent (ETWO), Emerald (EEX), Uxin (UXIN), NerdWallet (NRDS), Pursuit Attractions & Hospitality (PRSU), i3 Verticals (IIIV), Yext (YEXT), TELUS Digital (TIXT), Riskified (RSKD), and Tremor International (TRMR). These companies are all part of the "business services" industry. MaxCyte vs. E2open Parent Emerald Uxin NerdWallet Pursuit Attractions & Hospitality i3 Verticals Yext TELUS Digital Riskified Tremor International E2open Parent (NYSE:ETWO) and MaxCyte (NASDAQ:MXCT) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Do insiders and institutionals hold more shares of ETWO or MXCT? 68.8% of MaxCyte shares are owned by institutional investors. 4.7% of E2open Parent shares are owned by insiders. Comparatively, 3.0% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ETWO or MXCT? E2open Parent currently has a consensus target price of $2.53, indicating a potential downside of 6.48%. MaxCyte has a consensus target price of $7.50, indicating a potential upside of 244.04%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than E2open Parent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score E2open Parent 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75MaxCyte 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ETWO or MXCT? E2open Parent received 1 more outperform votes than MaxCyte when rated by MarketBeat users. However, 80.00% of users gave MaxCyte an outperform vote while only 26.00% of users gave E2open Parent an outperform vote. CompanyUnderperformOutperformE2open ParentOutperform Votes1326.00% Underperform Votes3774.00% MaxCyteOutperform Votes1280.00% Underperform Votes320.00% Is ETWO or MXCT more profitable? E2open Parent has a net margin of -74.63% compared to MaxCyte's net margin of -78.36%. E2open Parent's return on equity of 4.38% beat MaxCyte's return on equity.Company Net Margins Return on Equity Return on Assets E2open Parent-74.63% 4.38% 2.12% MaxCyte -78.36%-16.00%-13.93% Which has more risk and volatility, ETWO or MXCT? E2open Parent has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Does the media favor ETWO or MXCT? In the previous week, E2open Parent had 2 more articles in the media than MaxCyte. MarketBeat recorded 2 mentions for E2open Parent and 0 mentions for MaxCyte. E2open Parent's average media sentiment score of 1.45 beat MaxCyte's score of 0.18 indicating that E2open Parent is being referred to more favorably in the media. Company Overall Sentiment E2open Parent Positive MaxCyte Neutral Which has better valuation & earnings, ETWO or MXCT? MaxCyte has lower revenue, but higher earnings than E2open Parent. MaxCyte is trading at a lower price-to-earnings ratio than E2open Parent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioE2open Parent$607.69M1.53-$1.07B-$2.14-1.26MaxCyte$37.68M6.15-$37.92M-$0.40-5.45 SummaryE2open Parent and MaxCyte tied by winning 9 of the 18 factors compared between the two stocks. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$231.78M$2.98B$5.43B$8.48BDividend YieldN/A2.27%5.22%4.11%P/E Ratio-6.41105.7626.8220.05Price / Sales6.15164.75393.28116.44Price / CashN/A34.5738.2534.62Price / Book0.982.426.874.61Net Income-$37.92M$113.28M$3.22B$248.19M7 Day Performance-0.91%1.77%6.81%2.97%1 Month Performance-15.18%2.52%13.71%16.58%1 Year Performance-52.81%-8.44%18.30%8.16% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyte2.4644 of 5 stars$2.20+0.9%$7.50+240.9%-54.1%$233.90M$37.68M-6.4780High Trading VolumeETWOE2open Parent1.2612 of 5 stars$2.73+3.6%$2.53-7.3%-46.1%$937.37M$607.69M-1.833,680Positive NewsEEXEmerald1.1921 of 5 stars$4.70+0.1%$7.90+68.3%-21.7%$933.64M$413.10M-8.69600UXINUxin0.6577 of 5 stars$4.84+6.1%N/A+47.9%$909.03M$1.63B-0.24810Gap UpNRDSNerdWallet3.1067 of 5 stars$11.85+6.9%$15.00+26.6%-20.6%$878.18M$734.90M29.63770Positive NewsPRSUPursuit Attractions & Hospitality1.623 of 5 stars$30.39+5.1%$50.00+64.5%N/A$857.00M$366.49M60.783,390High Trading VolumeIIIVi3 Verticals4.0984 of 5 stars$25.36-1.2%$29.86+17.7%+34.2%$838.76M$236.56M5.651,640High Trading VolumeYEXTYext2.6468 of 5 stars$6.70+0.8%$9.00+34.4%+24.1%$834.14M$420.96M-44.631,400News CoveragePositive NewsAnalyst ForecastGap UpTIXTTELUS Digital2.9337 of 5 stars$2.97+9.6%$4.07+36.9%-55.0%$818.96M$2.66B-8.4973,100Gap DownRSKDRiskified2.514 of 5 stars$4.85+0.6%$5.66+16.6%-16.6%$781.86M$327.52M-24.25780Earnings ReportAnalyst RevisionGap DownTRMRTremor InternationalN/AN/AN/AN/A$726.18M$343.77M-71.43167 Related Companies and Tools Related Companies E2open Parent Alternatives Emerald Alternatives Uxin Alternatives NerdWallet Alternatives Pursuit Attractions & Hospitality Alternatives i3 Verticals Alternatives Yext Alternatives TELUS Digital Alternatives Riskified Alternatives Tremor International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MXCT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MXCT Stock Free MXCT Stock Alerts